Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 34,000 | |||
5 mg | 在庫あり | ¥ 104,500 | |||
10 mg | 在庫あり | ¥ 154,500 | |||
25 mg | 在庫あり | ¥ 243,500 | |||
50 mg | 在庫あり | ¥ 328,500 | |||
100 mg | 在庫あり | ¥ 441,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 90,000 |
説明 | Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM. |
ターゲット&IC50 | HIV-1 (IN):12.6 uM |
In vitro | Protosappanin A (PsA) and Protosappanin B (PsB) were identified from Sappan Lignum extracts. They showed activity against both S. aureus and MRSA with MIC or MIC50 at 64 (PsA) and 128 (PsB) mg/L alone. When they were used in combination with antibiotics, they showed the best synergy with amikacin and gentamicin with MIC50 (mg/L) of amikacin reduced more significantly from 32 to four (with PsA) and eight (with PsB), and the fractional inhibitory concentration index (FICI) ranged between 0.078 and 0.500 (FICI50 = 0.375). Moreover, the resistance of MRSA towards amikacin and gentamicin could be reversed by the Clinical and Laboratory Standards Institute criteria. The combined bactericidal mode could as well be synergy. PsA and PsB showed very low cytotoxicity in comparison with their promising activity against MRSA[1]. |
植物由来 |
別名 | PTA |
分子量 | 272.25 |
分子式 | C15H12O5 |
CAS No. | 102036-28-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 225 mg/mL (826.45 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Protosappanin A 102036-28-2 Angiogenesis Apoptosis Chromatin/Epigenetic Immunology/Inflammation JAK/STAT signaling Microbiology/Virology Neuroscience NF-Κb Proteases/Proteasome Stem Cells STAT NADPH-oxidase NO Synthase JAK IL Receptor HIV Protease COX ROS TLR NF-κB TNF IκB/IKK inhibit Inhibitor PTA Janus kinase inhibitor